Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $8.31 and traded as high as $9.09. Theravance Biopharma shares last traded at $8.91, with a volume of 184,700 shares changing hands.

Analyst Ratings Changes

A number of research analysts have issued reports on TBPH shares. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. Leerink Partnrs downgraded Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday, August 10th. TD Cowen reduced their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating for the company in a research report on Tuesday, August 6th. Finally, Leerink Partners downgraded shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Theravance Biopharma has an average rating of "Hold" and an average price target of $13.75.

Theravance Biopharma Stock Performance

The business's 50 day moving average price is $8.32 and its 200-day moving average price is $8.68. The firm has a market capitalization of $484.82 million, a PE ratio of -9.92 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.16). The company had revenue of $16.87 million during the quarter, compared to analysts' expectations of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. During the same period last year, the firm posted ($0.17) earnings per share. As a group, analysts anticipate that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. grew its holdings in Theravance Biopharma by 41.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company's stock worth $5,005,000 after acquiring an additional 163,951 shares in the last quarter. Marshall Wace LLP grew its holdings in Theravance Biopharma by 83.6% during the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company's stock worth $2,523,000 after acquiring an additional 135,426 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Theravance Biopharma during the 2nd quarter worth approximately $986,000. Algert Global LLC acquired a new position in Theravance Biopharma during the 3rd quarter worth approximately $851,000. Finally, Bank of Montreal Can grew its holdings in Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company's stock worth $1,414,000 after acquiring an additional 93,702 shares in the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.